Mark Sculpher, MSc
Professor, Centre for Health Economics
University of York

“Is NICE Doing More Harm than Good to Population Health? ”

Tuesday, February 10, 2015
4:00 pm-5:00 pm

Health Sciences
Turner Auditorium
Room D-209

Mark Sculpher is Professor of Health Economics at the Centre for Health Economics, University of York, UK where he is Director of the Programme on Economic Evaluation and Health Technology Assessment. He is also a Director at Oxford Outcomes, a consulting company specialising in health economics, epidemiology, patient reported outcomes and translation. Mark has worked in the field of economic evaluation and health technology assessment for over 25 years. He has researched in a range of clinical areas including heart disease and various types of cancer. He has also contributed to methods in the field, in particular relating to decision analytic modelling and techniques to handle uncertainty. He has over 200 peer-reviewed publications and is a co-author of two major text books in the area: Methods for the Economic Evaluation of Health Care Programmes (OUP, 2005 with Drummond, Torrance, O’Brien and Stoddart) and Decision Modelling for Health Economic Evaluation (OUP, 2006 with Briggs and Claxton). Mark is a member of the UK National Institute of Health Research (NIHR) College of Senior Investigators. He has also been a member of the National Institute for Health and Clinical Excellence (NICE) Technology Appraisal Committee and the NICE Public Health Interventions Advisory Committee. He currently sits on NICE’s Diagnostics Advisory Committee. He chaired NICE’s 2004 Task Group on methods guidance for economic evaluation and advised the Methods Working Party for the 2008 update of this guidance; he has also advised health systems internationally on HTA methods including those in Ireland, Germany, Portugal and New Zealand. He has been a member of the Commissioning Board for the UK NHS Health Technology Assessment Programme and currently sits on the UK NIHR/Medical Research Council’s Methodology Research Panel. He is Past President of the International Society of Phar-macoconomics and Outcomes Research (ISPOR).